Nano-Biofungicides and Bio-Nanofungicides: State of the Art of Innovative Tools for Controlling Resistant Phytopathogens

preprint OA: closed CC-BY-4.0
🔓 Open OA copy View at publisher
AI-generated summary by claude@2026-07, 2026-07-15

This review summarizes advances in nano-biofungicides and bio-nanofungicides, detailing their composition, enhanced efficacy against resistant phytopathogens, and challenges for sustainable agriculture.

One-sentence paraphrase of the abstract; not a substitute for reading it. No clinical advice. How this works

Abstract

Fungal diseases pose a significant threat to global agriculture, leading to substantial crop losses and endangering food security worldwide. Conventional chemical fungicides, while effective, are increasingly criticized for their detrimental environmental impacts, including soil degradation, water contamination, and the disruption of non-target organisms. Additionally, the overuse of these fungicides has accelerated the emergence of resistant fungal strains, further challenging disease management strategies. In response to these issues, bio-nanofungicides and nano-biofungicides have emerged as a cutting-edge solution, combining biocompatibility, environmental safety, and enhanced efficacy. These advanced formulations integrate bio-based agents, such as microbial metabolites or plant extracts, with nanotechnology to improve their stability, controlled release, and targeted delivery. Nanoparticles such as chitosan, silica, and silver have been extensively studied for their ability to encapsulate bioactive compounds, enhancing their antifungal activity while minimizing environmental residues. Recent studies have demonstrated nano-based fungicides' potential to address critical gaps in sustainable agriculture, with promising applications in integrated pest management systems. Here, we summarize the las advances in the development of bio-nanofungicides and nano-biofungicides and analyzed the main differences between them. I addition, challenges such as large-scale production, regulatory approval, and comprehensive risk assessments remain are discussed.

My notes (saved in your browser only)

Citation neighborhood (no data yet)

We don't have any in-corpus citations linked to this paper yet. This is a recent paper (2025) — citers typically take a year or two to land, and the OpenAlex reference graph may still be filling in.

Source provenance

europepmc
last seen: 2026-05-20T01:45:00.602351+00:00
unpaywall
last seen: 2026-05-22T02:00:06.705733+00:00
License: CC-BY-4.0